Clinical Trials Logo

Filter by:
NCT ID: NCT03393520 Completed - Clinical trials for Agitation in Patients With Dementia of the Alzheimer's Type

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Start date: October 13, 2017
Phase: Phase 3
Study type: Interventional

This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in participants with dementia of the Alzheimer's type.

NCT ID: NCT03393013 Completed - Clinical trials for Systemic Lupus Erythematosus

A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

MISSION
Start date: February 20, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This was a Phase 1b/2, multi-center study in which patients received KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2).

NCT ID: NCT03392428 Completed - Metastatic Cancer Clinical Trials

A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer

TheraP
Start date: January 29, 2018
Phase: Phase 2
Study type: Interventional

This open label, randomised, stratified, 2-arm, multicentre, phase 2 trial aims to determine the activity and safety of Lu-PSMA vs cabazitaxel in men with progressive metastatic castration resistant prostate cancer

NCT ID: NCT03392142 Completed - Clinical trials for Stem Cell Transplant Complications

Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab

MATCH
Start date: December 29, 2017
Phase: Phase 3
Study type: Interventional

This is a multicenter, open label, single-arm, phase 3 study to assess the efficacy and safety of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.

NCT ID: NCT03392116 Completed - Cachexia Clinical Trials

Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

Start date: January 29, 2018
Phase: Phase 1
Study type: Interventional

The purpose is to evaluate the safety, tolerability, and PK of NGM120 in healthy adult subjects

NCT ID: NCT03391778 Recruiting - Neoplasms Clinical Trials

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Start date: April 9, 2018
Phase: Phase 1
Study type: Interventional

This trial will evaluate long term safety of participants who have received GlaxoSmithKline (GSK) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

NCT ID: NCT03391765 Terminated - Clinical trials for Progressive Supranuclear Palsy (PSP)

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

Start date: January 24, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the long-term safety and efficacy of ABBV-8E12 (tilavonemab) in participants with progressive supranuclear palsy (PSP).

NCT ID: NCT03391466 Active, not recruiting - Clinical trials for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

ZUMA-7
Start date: January 25, 2018
Phase: Phase 3
Study type: Interventional

The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

NCT ID: NCT03390504 Active, not recruiting - Urothelial Cancer Clinical Trials

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

THOR
Start date: March 23, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-[L]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).

NCT ID: NCT03386344 Terminated - Clinical trials for Type 2 Diabetes Mellitus

Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

SOTA-BONE
Start date: February 19, 2018
Phase: Phase 3
Study type: Interventional

The primary objective is to demonstrate the superiority of Sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1c (Hb1Ac) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control on diet and exercise only or with a stable antidiabetes regimen.